Critical evaluation of the DNA-methylation markers ABCG1 and SREBF1 for Type 2 diabetes stratification

Christin Krause; Helen Sievert; Cathleen Geißler; Martina Grohs; Alexander T. El Gammal; Stefan Wolter; Olena Ohlei; Fabian Kilpert; Ulrike M. Krämer; Meike Kasten; Christine Klein; Georg E. Brabant; Oliver Mann; Hendrik Lehnert; Henriette Kirchner

doi:10.2217/epi-2018-0159

Critical evaluation of the DNA-methylation markers ABCG1 and SREBF1 for Type 2 diabetes stratification

Christin Krause, Helen Sievert, Cathleen Geißler, Martina Grohs, Alexander T. El Gammal, Stefan Wolter, Olena Ohlei, Fabian Kilpert, Ulrike M. Krämer, Meike Kasten, Christine Klein, Georg E. Brabant, Oliver Mann, Hendrik Lehnert, Henriette Kirchner^*

^*Corresponding author for this work

University Hospital Hamburg-Eppendorf

Abstract

Aim: Validation of epigenome-wide association studies is sparse. Therefore, we evaluated the methylation markers cg06500161 (ABCG1) and cg11024682 (SREBF1) as classifiers for diabetes stratification. Patients & methods: DNA methylation was measured in blood (n = 167), liver (n = 99) and visceral adipose tissue (n = 99) of nondiabetic or Type 2 diabetic subjects by bisulfite pyrosequencing. Results: DNA methylation at cg11024682 in blood and liver correlated with BMI. Methylation at cg06500161 was influenced by the adjacent SNP rs9982016. Insulin-resistant and sensitive subjects could be stratified by DNA methylation status in blood or visceral adipose tissue. Conclusion: DNA methylation at both loci in blood presents a promising approach for risk group stratification and could be valuable for personalized Type 2 diabetes risk prediction in the future.

Original language	English
Journal	Epigenomics
Volume	11
Issue number	8
Pages (from-to)	885-897
Number of pages	13
ISSN	1750-1911
DOIs	https://doi.org/10.2217/epi-2018-0159
Publication status	Published - 01.06.2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/epi-2018-0159

Cite this

Krause, C., Sievert, H., Geißler, C., Grohs, M., El Gammal, A. T., Wolter, S., Ohlei, O., Kilpert, F., Krämer, U. M., Kasten, M., Klein, C., Brabant, G. E., Mann, O., Lehnert, H., & Kirchner, H. (2019). Critical evaluation of the DNA-methylation markers ABCG1 and SREBF1 for Type 2 diabetes stratification. Epigenomics, 11(8), 885-897. https://doi.org/10.2217/epi-2018-0159

@article{6272ac5ae46e429b84f7fd2fe6f8b9ee,

title = "Critical evaluation of the DNA-methylation markers ABCG1 and SREBF1 for Type 2 diabetes stratification",

abstract = "Aim: Validation of epigenome-wide association studies is sparse. Therefore, we evaluated the methylation markers cg06500161 (ABCG1) and cg11024682 (SREBF1) as classifiers for diabetes stratification. Patients & methods: DNA methylation was measured in blood (n = 167), liver (n = 99) and visceral adipose tissue (n = 99) of nondiabetic or Type 2 diabetic subjects by bisulfite pyrosequencing. Results: DNA methylation at cg11024682 in blood and liver correlated with BMI. Methylation at cg06500161 was influenced by the adjacent SNP rs9982016. Insulin-resistant and sensitive subjects could be stratified by DNA methylation status in blood or visceral adipose tissue. Conclusion: DNA methylation at both loci in blood presents a promising approach for risk group stratification and could be valuable for personalized Type 2 diabetes risk prediction in the future.",

author = "Christin Krause and Helen Sievert and Cathleen Gei{\ss}ler and Martina Grohs and {El Gammal}, {Alexander T.} and Stefan Wolter and Olena Ohlei and Fabian Kilpert and Kr{\"a}mer, {Ulrike M.} and Meike Kasten and Christine Klein and Brabant, {Georg E.} and Oliver Mann and Hendrik Lehnert and Henriette Kirchner",

year = "2019",

month = jun,

day = "1",

doi = "10.2217/epi-2018-0159",

language = "English",

volume = "11",

pages = "885--897",

journal = "Epigenomics",

issn = "1750-1911",

number = "8",

}

TY - JOUR

T1 - Critical evaluation of the DNA-methylation markers ABCG1 and SREBF1 for Type 2 diabetes stratification

AU - Krause, Christin

AU - Sievert, Helen

AU - Geißler, Cathleen

AU - Grohs, Martina

AU - El Gammal, Alexander T.

AU - Wolter, Stefan

AU - Ohlei, Olena

AU - Kilpert, Fabian

AU - Krämer, Ulrike M.

AU - Kasten, Meike

AU - Klein, Christine

AU - Brabant, Georg E.

AU - Mann, Oliver

AU - Lehnert, Hendrik

AU - Kirchner, Henriette

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Aim: Validation of epigenome-wide association studies is sparse. Therefore, we evaluated the methylation markers cg06500161 (ABCG1) and cg11024682 (SREBF1) as classifiers for diabetes stratification. Patients & methods: DNA methylation was measured in blood (n = 167), liver (n = 99) and visceral adipose tissue (n = 99) of nondiabetic or Type 2 diabetic subjects by bisulfite pyrosequencing. Results: DNA methylation at cg11024682 in blood and liver correlated with BMI. Methylation at cg06500161 was influenced by the adjacent SNP rs9982016. Insulin-resistant and sensitive subjects could be stratified by DNA methylation status in blood or visceral adipose tissue. Conclusion: DNA methylation at both loci in blood presents a promising approach for risk group stratification and could be valuable for personalized Type 2 diabetes risk prediction in the future.

AB - Aim: Validation of epigenome-wide association studies is sparse. Therefore, we evaluated the methylation markers cg06500161 (ABCG1) and cg11024682 (SREBF1) as classifiers for diabetes stratification. Patients & methods: DNA methylation was measured in blood (n = 167), liver (n = 99) and visceral adipose tissue (n = 99) of nondiabetic or Type 2 diabetic subjects by bisulfite pyrosequencing. Results: DNA methylation at cg11024682 in blood and liver correlated with BMI. Methylation at cg06500161 was influenced by the adjacent SNP rs9982016. Insulin-resistant and sensitive subjects could be stratified by DNA methylation status in blood or visceral adipose tissue. Conclusion: DNA methylation at both loci in blood presents a promising approach for risk group stratification and could be valuable for personalized Type 2 diabetes risk prediction in the future.

UR - http://www.scopus.com/inward/record.url?scp=85068170068&partnerID=8YFLogxK

U2 - 10.2217/epi-2018-0159

DO - 10.2217/epi-2018-0159

M3 - Journal articles

C2 - 31169416

AN - SCOPUS:85068170068

SN - 1750-1911

VL - 11

SP - 885

EP - 897

JO - Epigenomics

JF - Epigenomics

IS - 8

ER -

Critical evaluation of the DNA-methylation markers ABCG1 and SREBF1 for Type 2 diabetes stratification

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this